<DOC>
	<DOCNO>NCT00476957</DOCNO>
	<brief_summary>The PROTECT TRIAL randomize stent trial 8800 patient approximately 200 hospital , design evaluate whether Endeavor stent PROTECTS late stent thrombosis result less deaths myocardial infarction . Study Stents : Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System next generation model Cordis Cypher® Sirolimus-eluting Coronary Stent , Cordis Cypher Select® Sirolimus-eluting Coronary Stent next generation model Primary Objective : To compare overall stent thrombosis rate Endeavor® Zotarolimus Eluting Coronary Stent System versus Cypher® Sirolimus-eluting Coronary Stent patient population require stent implantation Secondary Objective : To compare composite endpoint total death cardiac death combine number patient non-fatal myocardial infarction well number patient large non-fatal myocardial infarction Endeavor® Zotarolimus Eluting Coronary Stent System versus Cypher® Sirolimus-eluting Coronary Stent patient population require stent implantation . To assess safety efficacy patient subgroup specific demographic , clinical indication and/or vessel- lesion characteristic .</brief_summary>
	<brief_title>Randomized Study Comparing Endeavor With Cypher Stents ( PROTECT )</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patient &gt; 18 year age ( minimum age require local regulation ) . 2 . The patient consent participate authorize collection release medical information sign `` Patient Informed Consent Form '' . 3 . All lesion require intervention ( target lesion one maximum four ) one native coronary artery amendable implantation one Endeavor® Zotarolimus Eluting Coronary Stent System Cypher® Sirolimuseluting Coronary Stent* . 4 . Patient indication , lesion length vessel diameter target lesion ( ) accord 'Indications Use ' mention 'Instructions Use ' come every Endeavor® Zotarolimus Eluting Coronary Stent System Cypher® Sirolimuseluting Coronary Stent . Patients qualify system randomization* . 5 . The patient willing able cooperate study procedure require follow visit . 1 . Women know pregnancy lactate . 2 . Planned elective surgery necessitate discontinuation clopidogrel within regular planned period clopidogrel administration . 3 . Patients expect compliant antiplatelet and/or anticoagulation therapy regimen . 4 . Previous brachytherapy . 5 . Previous implantation drug elute stent . 6 . Previous implantation bare metal stent precede year . 7 . Simultaneous plan intervention non cardiac vessel include limited renal artery carotid artery . 8 . Current medical condition life expectancy le 3 year . 9 . Manifest acute severe heart failure ( Killip class IIIIV ) . 10 . The patient currently , first 3 year PROTECT trial , participate another investigational device drug study clinically interfere PROTECTstudy endpoint ; require coronary angiography coronary artery imaging procedure . The patient may enrol PROTECTstudy . 11 . Patients medical condition preclude followup define protocol otherwise limit participation study . 12 . Patients warfarin similar anticoagulant therapy . 13 . Patients hypersensitivity allergies one drug component indicate Instructions Use either stent . 14 . Patients judged lesion prevents complete inflation angioplasty balloon . 15 . Patients antiplatelet and/or anticoagulation therapy contraindicate . 16 . Transplant patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Drug Eluting Stents</keyword>
	<keyword>Interventional Cardiology</keyword>
</DOC>